Leslie Wilson, PhD

Professor
Department of Clinical Pharmacy
[email protected]
Phone: +1 415 990-1012
Fax: +1 415 502-0792
490 Illinois Street, Rm 32F
UCSF Box 0613
San Francisco, CA 94158
United States

Links

Patient Prosthetic Preferences Studies UCSF Profiles

Affiliations

Education programs

PharmD Degree Program

UCSF centers, institutes, and research programs

Director, Program for Outcomes, Pharmaceutical Economics, and Policy Studies (PrOPEPS)

What I do

My research focuses on the economics of health care services, measurement of outcomes, comparative effectiveness, cost-effectiveness, utility measurement, decision making under uncertainty, and patient preference when weighing risks and benefits.

Departmental research area

health services and policy research

My research expertise

economics and outcome analyses

Clinical expertise

economics, health policy

Professional background

Degrees

PhD, Health Policy and Economics, University of Maryland, 1989

Biography

Dr. Leslie Wilson is a Professor in the Department of Medicine and the Department of Clinical Pharmacy, School of Pharmacy at the University of California, San Francisco. Prior to joining the faculty at UCSF, she was the Director of Health Economics for Miles Inc. and also for Bayer AG. Dr. Wilson received her Ph.D. in health policy and economics from the University of Maryland. Her current research focuses on economic and outcome analyses including the cost of illness and cost effectiveness analyses of cancer and specific chronic diseases (including rare diseases) and how new diagnostics, treatments, and patterns of care affect the costs and outcomes of these diseases. She also looks at the epidemiology, risks and economics of Valley Fever, and also Chagas disease and its treatment in developing countries and in the U.S. blood supply. She also looks patient preference and decision making; specifically how patients weigh risks and benefits when making on treatment choices. Dr. Wilson is working with the FDA to help incorporate patient preference into approval of devices. In addition, Dr. Wilson studies the economics of policy issues, including the effects of drug legislation within the California Workers’ Compensation System, and cultural competence in California medical, dental and pharmacy schools. Dr. Wilson was instrumental in bringing health economics into the current and new pharmacy curriculum and teaches a course on decision analysis modeling and an elective and independent study on research in health economics. She is the developer and Co-Director of the Program for Pharmaceutical Economics and Policy Studies(ProPEPS) whose purpose is to organize the development of economic and policy research, teaching , and funding within the Department of Clinical Pharmacy. She works with the Department of Urology on the economic issues in treatment of prostate cancer, with the Department of Neurology on a CMS innovation grant looking at new economic models of dementia care, and with the Osher Center on the economics of integrative medicine treatments.

Research keywords

  • Low Back Pain
  • Fee Schedules
  • Cost-Benefit Analysis
  • Choice Behavior
  • Models, Economic
  • Drug Costs
  • excipients
  • Drug Compounding
  • Patient Preference
  • Insulins
  • Quality-Adjusted Life Years
  • Decision Making
  • prescription drugs
  • Workers' Compensation
  • Prostatic Neoplasms

Publications

Wilson L, Denham A, Ionova Y, O'Neill C, Greco CM, Hassett AL, Hanmer J, Shaikh S, Wolf M, Berven S, Williams D, Ma Y, Lotz J, Zheng P. Preferences for risks and benefits of treatment outcomes for chronic low back pain: Choice-based conjoint measure development and discrete choice experiment. PM R. 2024 Aug; 16(8):836-847.
Wilson L, Gress AF, Frassetto L, Sarathy H, Gress EA, Fissell WH, Roy S. Patient Preference Trade-offs for Next-Generation Kidney Replacement Therapies. Clin J Am Soc Nephrol. 2024 Jan 01; 19(1):76-84.
Wilson L, Zheng P, Ionova Y, Denham A, Yoo C, Ma Y, Greco CM, Hanmer J, Williams DA, Hassett AL, Scheffler AW, Valone F, Mehling W, Berven S, Lotz J, O'Neill C. CAPER: patient preferences to inform nonsurgical treatment of chronic low back pain: a discrete-choice experiment. Pain Med. 2023 08 01; 24(8):963-973.
Wilson L, Dohan D, Garibaldi M, Szeto D, Timmerman M, Matheny J. Prosthesis preferences for those with upper limb loss: Discrete choice study of PULLTY® for use in regulatory decisions. J Rehabil Assist Technol Eng. 2023 Jan-Dec; 10:20556683231152418.
Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, Broering J, Carroll PR, Sanda M, Wilson L. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence. Eur J Cancer Care (Engl). 2022 Nov; 31(6):e13740.
Wilson L, Kwok T, Ma Y, Wong J, Ho M, Ionova Y, McGrath M, Mueller MM, Gitelman SE, Irony T. Preferences for Risks and Benefits of Islet Cell Transplantation for Persons With Type 1 Diabetes With History of Episodes of Severe Hypoglycemia: A Discrete-Choice Experiment to Inform Regulatory Decisions. Transplantation. 2022 08 01; 106(8):e368-e379.
Ionova Y, Peterson T, Wilson L. Analyzing excipient-related adverse events in antiseizure drug formulations. Epilepsy Res. 2022 08; 184:106947.
Ionova Y, Vuong W, Sandoval O, Fong J, Vu V, Zhong L, Wilson L. Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA. Clin Drug Investig. 2022 Jun; 42(6):491-500.
Chan A, Dang C, Wisniewski J, Weng X, Hynson E, Zhong L, Wilson L. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. Am J Clin Oncol. 2022 02 01; 45(2):66-73.
Narsipur N, Bulla S, Yoo C, Do B, Tran K, Gu D, Zhong L, Wilson L. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021 Dec; 27(12):1691-1702.
Jeong E, Wang C, Wilson L, Zhong L. Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. Front Oncol. 2021; 11:658054.
Golden NH, Cheng J, Kapphahn CJ, Buckelew SM, Machen VI, Kreiter A, Accurso EC, Adams SH, Le Grange D, Moscicki AB, Sy AF, Wilson L, Garber AK. Higher-Calorie Refeeding in Anorexia Nervosa: 1-Year Outcomes From a Randomized Controlled Trial. Pediatrics. 2021 04; 147(4).
Li M, Lin S, Wilson L, Huang P, Wang H, Lai S, Dong L, Xu X, Weng X. Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion. Front Oncol. 2021; 11:562135.
Le V, Zhong L, Narsipur N, Hays E, Tran DK, Rosario K, Wilson L. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer. J Manag Care Spec Pharm. 2021 Mar; 27(3):327-338.
Berry DL, Hong F, Blonquist TM, Halpenny B, Xiong N, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urol Oncol. 2021 08; 39(8):493.e9-493.e15.
Garber AK, Cheng J, Accurso EC, Adams SH, Buckelew SM, Kapphahn CJ, Kreiter A, Le Grange D, Machen VI, Moscicki AB, Sy A, Wilson L, Golden NH. Short-term Outcomes of the Study of Refeeding to Optimize Inpatient Gains for Patients With Anorexia Nervosa: A Multicenter Randomized Clinical Trial. JAMA Pediatr. 2021 01 01; 175(1):19-27.
Grizzle AJ, Wilson L, Nix DE, Galgiani JN. Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis. Open Forum Infect Dis. 2021 Feb; 8(2):ofaa623.
Ionova Y, Wilson L. Biologic excipients: Importance of clinical awareness of inactive ingredients. PLoS One. 2020; 15(6):e0235076.
Jeong CW, Herlemann A, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa044.
Sanchez JM, Shah R, Kouassi Y, Chronowic M, Wilson L, Marcus GM. A cost-effectiveness analysis comparing a conventional mechanical needle to a radiofrequency device for transseptal punctures. J Cardiovasc Electrophysiol. 2020 07; 31(7):1672-1677.
Wilson L, Lin L, Singh K. The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process. Clin Pharmacol Ther. 2020 01; 107(1):82-84.
Ten Ham RMT, Broering JM, Cooperberg MR, Carroll P, Wilson LS. Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clin Genitourin Cancer. 2020 02; 18(1):e21-e27.
Garber AK, Cheng J, Accurso EC, Adams SH, Buckelew SM, Kapphahn CJ, Kreiter A, Le Grange D, Machen VI, Moscicki AB, Saffran K, Sy AF, Wilson L, Golden NH. Weight Loss and Illness Severity in Adolescents With Atypical Anorexia Nervosa. Pediatrics. 2019 12; 144(6).
Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. Eur Urol. 2019 12; 76(6):743-751.
Lin TK, Shoair OA, Tran D, Wilson L. Utilization, Cost, and Pricing Scheme of Compounded Medications for Public Health System Patients: The California Workers' Compensation System, 2011-2013. J Manag Care Spec Pharm. 2019 Jul; 25(7):743-751.
Chen Y, Wilson L, Kornak J, Dudley RA, Merrilees J, Bonasera SJ, Byrne CM, Lee K, Chiong W, Miller BL, Possin KL. The costs of dementia subtypes to California Medicare fee-for-service, 2015. Alzheimers Dement. 2019 07; 15(7):899-906.
Wilson L, Turkistani F, Tran DM, Huang W, Lin TK. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System. Appl Health Econ Health Policy. 2019 04; 17(2):231-242.
Wilson L, Ting J, Lin H, Shah R, MacLean M, Peterson MW, Stockamp N, Libke R, Brown P. The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. Int J Environ Res Public Health. 2019 03 28; 16(7).
Tang J, Zhong L, Paoli C, Paciorek A, Carroll P, Wilson L. Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. Am J Mens Health. 2019 Mar-Apr; 13(2):1557988319835326.
Wilson LS, Blonquist TM, Hong F, Halpenny B, Wolpin S, Chang P, Filson CP, Master VA, Sanda MG, Chien GW, Jones RA, Krupski TL, Berry DL. Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. BMC Med Inform Decis Mak. 2019 01 09; 19(1):6.
Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. J Am Coll Clin Pharm. 2019 Jun; 2(3):214-221.
Tran JLA, Sheng R, Beaulieu A, Villodas M, McBurnett K, Pfiffner LJ, Wilson L. Cost-Effectiveness of a Behavioral Psychosocial Treatment Integrated Across Home and School for Pediatric ADHD-Inattentive Type. Adm Policy Ment Health. 2018 09; 45(5):741-750.
Christopoulos KA, Riley ED, Carrico AW, Tulsky J, Moskowitz JT, Dilworth S, Coffin LS, Wilson L, Peretz JJ, Hilton JF. A Randomized Controlled Trial of a Text Messaging Intervention to Promote Virologic Suppression and Retention in Care in an Urban Safety-Net Human Immunodeficiency Virus Clinic: The Connect4Care Trial. Clin Infect Dis. 2018 08 16; 67(5):751-759.
Lin TK, Wilson L. Use and Costs of Medical Foods and Convenience-Packaged Drugs in the California Workers' Compensation System. J Manag Care Spec Pharm. 2018 Aug; 24(8):819-833.
Wilson L, Lin TK, Oh A, Cao V. A gray area for reimbursement: medical foods for non-inborn errors of metabolism. Am J Manag Care. 2018 07; 24(8 Spec No.):SP273-SP278.
Wilson L, Turkistani FA, Huang W, Tran DM, Lin TK. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing. PLoS One. 2018; 13(5):e0197449.
Roubinov DS, Felder JN, Vieten C, Coleman-Phox K, Laraia B, Adler N, Wilson L, Epel E, Bush NR. Maternal depressive symptoms and infant healthcare utilization: The moderating role of prenatal mindfulness. Gen Hosp Psychiatry. 2018 Jul - Aug; 53:82-83.
Chung PJ, Song C, Miller HP, Li Y, Raviv U, Choi MC, Wilson L, Feinstein SC, Safinya CR. Synchrotron small-angle X-ray scattering and electron microscopy characterization of structures and forces in microtubule/Tau mixtures. Methods Cell Biol. 2017; 141:155-178.
Johnson FR, Beusterien K, Özdemir S, Wilson L. Giving Patients a Meaningful Voice in United States Regulatory Decision Making: The Role for Health Preference Research. Patient. 2017 08; 10(4):523-526.
Berry DL, Hong F, Blonquist TM, Halpenny B, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M, Somayaji P. Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. J Urol. 2018 01; 199(1):89-97.
Cook B, Proctor D, Bromberg R, LaPointe NE, Feinstein SC, Wilson L. Digital quantification of neurite outgrowth and retraction by phase-contrast microscopy: A tau perspective. Methods Cell Biol. 2017; 141:217-228.
Hampson LA, Lin TK, Wilson L, Allen IE, Gaither TW, Breyer BN. Understanding patients' preferences for surgical management of urethral stricture disease. World J Urol. 2017 Nov; 35(11):1799-1805.
Wilson L, Huang W, Chen L, Ting J, Cao V. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid. 2017 08; 27(8):1043-1052.
Oh A, Tran DM, McDowell LC, Keyvani D, Barcelon JA, Merino O, Wilson L. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. J Manag Care Spec Pharm. 2017 Jun; 23(6):653-664.
Possin KL, Merrilees J, Bonasera SJ, Bernstein A, Chiong W, Lee K, Wilson L, Hooper SM, Dulaney S, Braley T, Laohavanich S, Feuer JE, Clark AM, Schaffer MW, Schenk AK, Heunis J, Ong P, Cook KM, Bowhay AD, Gearhart R, Chodos A, Naasan G, Bindman AB, Dohan D, Ritchie C, Miller BL. Development of an adaptive, personalized, and scalable dementia care program: Early findings from the Care Ecosystem. PLoS Med. 2017 03; 14(3):e1002260.
Wilson L, Lin T, Wang L, Patel T, Tran D, Kim S, Dacey K, Yuen C, Kroon L, Brodowy B, Rodondi K. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center. J Manag Care Spec Pharm. 2017 Feb; 23(2):163-169.
Wilson L, Lin TK, Hampson LA, Oh A, Ting J, Gaither T, Allen I, Breyer BN. Use of Conjoint Analysis to Determine Patient Preferences for Surgical Treatment of Urethral Stricture Disease. J Particip Med. 2017; 9.
Hampson LA, Allen IE, Gaither TW, Lin T, Ting J, Osterberg EC, Wilson L, Breyer BN. Patient-centered Treatment Decisions for Urethral Stricture: Conjoint Analysis Improves Surgical Decision-making. Urology. 2017 Jan; 99:246-253.
Sánchez-González G, Figueroa-Lara A, Elizondo-Cano M, Wilson L, Novelo-Garza B, Valiente-Banuet L, Ramsey JM. Cost-Effectiveness of Blood Donation Screening for Trypanosoma cruzi in Mexico. PLoS Negl Trop Dis. 2016 Mar; 10(3):e0004528.
Ting J, Wilson L, Schwarzenberg SJ, Himes R, Barth B, Bellin MD, Durie PR, Fishman DS, Freedman SD, Gariepy CE, Giefer MJ, Gonska T, Husain SZ, Kumar S, Morinville VD, Lowe ME, Ooi CY, Pohl JF, Troendle D, Usatin D, Werlin SL, Wilschanski M, Heyman MB, Uc A. Direct Costs of Acute Recurrent and Chronic Pancreatitis in Children in the INSPPIRE Registry. J Pediatr Gastroenterol Nutr. 2016 Mar; 62(3):443-9.
Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Value Health. 2015 Sep; 18(6):774-82.
Shih V, Ten Ham RM, Bui CT, Tran DN, Ting J, Wilson L. Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. J Skin Cancer. 2015; 2015:505302.
Li Y, Bare LA, Bender RA, Sninsky JJ, Wilson LS, Devlin JJ, Waldman FM. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Mol Diagn Ther. 2015 Jun; 19(3):169-77.
Zaid UB, Hawkins M, Wilson L, Ting J, Harris C, Alwaal A, Zhao LC, Morey AF, Breyer BN. The cost of surveillance after urethroplasty. Urology. 2015 May; 85(5):1195-1199.
Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82.
Christopoulos KA, Riley ED, Tulsky J, Carrico AW, Moskowitz JT, Wilson L, Coffin LS, Falahati V, Akerley J, Hilton JF. A text messaging intervention to improve retention in care and virologic suppression in a U.S. urban safety-net HIV clinic: study protocol for the Connect4Care (C4C) randomized controlled trial. BMC Infect Dis. 2014 Dec 31; 14:718.
Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7.
Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract. 2014 Dec; 20(6):417-25.
Broering JM, Paciorek A, Carroll PR, Wilson LS, Litwin MS, Miaskowski C. Measurement equivalence using a mixed-mode approach to administer health-related quality of life instruments. Qual Life Res. 2014 Mar; 23(2):495-508.
Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, Gong C, Malmstrom R, Wilson L. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One. 2013; 8(5):e64275.
Belkora J, Stupar L, O'Donnell S, Loucks A, Moore D, Jupiter C, Johnson N, Wilson L. Decision support by telephone: randomized controlled trial in a rural community setting. Patient Educ Couns. 2012 Oct; 89(1):134-42.
Wilson LS, Pregenzer M, Basu R, Bertenthal D, Torres J, Asgari M, Chren MM. Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting. Dermatol Surg. 2012 Apr; 38(4):570-84.
Wilson LS, Hensic L, Paoli CJ, Basu R, Christenson M, Moskowitz JT, Wara D. The effect of prophylaxis on pediatric HIV costs. AIDS Care. 2012; 24(1):108-18.
Wilson LS, Basu R, Christenson M, Hensic L, Paoli C, Wara D, Moskowitz JT. Pediatric HIV costs across three treatment eras from 1986 to 2007. Pediatrics. 2010 Sep; 126(3):e541-9.
Wilson LS, Ramsey JM, Koplowicz YB, Valiente-Banuet L, Motter C, Bertozzi SM, Tobler LH. Cost-effectiveness of implementation methods for ELISA serology testing of Trypanosoma cruzi in California blood banks. Am J Trop Med Hyg. 2008 Jul; 79(1):53-68.
Gitlin M, Wilson L. Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing options to physician and retail dispensing. Am J Ind Med. 2007 Apr; 50(4):303-15.
Mehling WE, Jacobs B, Acree M, Wilson L, Bostrom A, West J, Acquah J, Burns B, Chapman J, Hecht FM. Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage. 2007 Mar; 33(3):258-66.
Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007 Feb 01; 109(3):518-27.
Moskowitz JT, Butensky E, Harmatz P, Vichinsky E, Heyman MB, Acree M, Wrubel J, Wilson L, Folkman S. Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer. 2007 Jan; 48(1):64-71.
Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg. 2005 Nov; 73(5):901-10.
Wilson L, Gitlin M. New workers' compensation legislation: expected pharmaceutical cost savings. Am J Ind Med. 2005 Oct; 48(4):239-48.
Wilson LS, Moskowitz JT, Acree M, Heyman MB, Harmatz P, Ferrando SJ, Folkman S. The economic burden of home care for children with HIV and other chronic illnesses. Am J Public Health. 2005 Aug; 95(8):1445-52.
Heyman MB, Harmatz P, Acree M, Wilson L, Moskowitz JT, Ferrando S, Folkman S. Economic and psychologic costs for maternal caregivers of gastrostomy-dependent children. J Pediatr. 2004 Oct; 145(4):511-6.
Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jordan MA. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res. 2004 Jul 15; 64(14):4957-64.
Wilson L, Lin E, Lalwani A. Cost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery. Laryngoscope. 2003 Oct; 113(10):1736-45.
Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer. 2002 Nov 01; 95(9):1848-56.
Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002 Jan-Feb; 5(1):26-34.